Drug Trial Radar · NCT06209320
A Study of the Efficacy and Safety of Two Low-concentration Atropine Sulfate Eye Drops
Last checked: Nov 19, 2026Latest source record: Jul 30, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
777
Planned (sponsor's estimate)
Start
Mar 15, 2022
Primary completion
Mar 21, 2025
Study completion Aug 2025
Sponsor
- Lead sponsor
- Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jan 17, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 6 years, up to 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A randomized, double-blind, placebo-controlled, multicenter, phase III clinical study of the efficacy and safety of two low-concentration atropine sulfate eye drops in slowing the progression of myopia in children
Conditions
- Myopia
Interventions
Lower dose atropine sulfate eye dropsDrug
administer to eyes
Low dose atropine sulfate eye dropsDrug
administer to eyes
placeboDrug
administer to eyes
Primary outcomes
What the sponsor says the trial is designed to measure.
- Cycloplegic Autorefraction(SER)Time frame: 24 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Beijing Tongren Hospital, Capital Medical University
Beijing, Beijing Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.